Jointly provided by Postgraduate Institute for Medicine (PIM) and peerXchange.
This educational activity is supported by an independent educational grant from Merck.
Patients with inflammatory bowel disease (IBD) are at an increased risk for infections, however, some of these infections are preventable by vaccination. While immunocompetent IBD patients can generally be vaccinated using standard immunization recommendations, there are special considerations for IBD patients receiving immunosuppressive therapy; this is especially important when treatment includes biological therapies. The use of immunosuppressive therapy will influence vaccine recommendations and preventive care counseling by gastroenterologists and the primary care team.
Using interactive case scenarios, Gary R. Lichtenstein, MD, and Michael Cirigliano, MD, will explore vaccine-related issues that are relevant to patients with IBD being treated with immunosuppressive biological therapies.
This activity is designed to meet the educational needs of gastroenterologists, internists, family medicine and primary care physicians, nurse practitioners, and physician assistants who provide care to patients with IBD.
After completing this activity, the participant will be better able to:
Assess vaccination status and routine preventive care needs in patients with IBD in accordance with recommended schedules
Individualize vaccination recommendations in alignment with current guidelines to help mitigate the risk of vaccine-preventable infection in patients with IBD
Implement strategies that increase the frequency of guideline-compliant vaccination schedule completion for each IBD patient prior to initiating therapy
Coordinate responsibilities for vaccination recommendations, monitoring, and administration among clinicians that care for patients with IBD
Conflict Of Interest Disclosure Policy
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Gary R. Lichtenstein, MD Professor of Medicine Director, Center for Inflammatory Bowel Diseases The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania Hospital of the University of Pennsylvania Gastroenterology Division, Department of Internal Medicine Perelman Center for Advanced Medicine Philadelphia, PA
Dr. Lichtenstein reports the following: Consulting: Abbvie, Actavis, Alaven, CellCeutrix, Celgene, Ferring, Gilead, Hospira, Janssen Biotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, Takeda, UCB Contracted Research: Celgene, Janssen Biotech, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, UCB Other (Honorarium): Clinical Advances in Gastroenterology (Editor), Gastro-Hep Communications (Editor), Ironwood (CME Program), Luitpold/American Regent (CME Program), Merck (CME Program), McMahon Publishing (Author), Romark (CME), Springer Science and Business Media (Editor), Up-To-Date (Author) Funding to University of Pennsylvania: Janssen Biotech (IBD Fellow Education), Pfizer Pharmaceuticals (IBD Fellow Education), Takeda (IBD Fellow Education) Royalty: SLACK, Inc. (Book Royalty)
Michael Cirigliano, MD, FACP Founder's Associate Professor of General Internal Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA
Dr. Cirigliano reports the following: Fees for Non-CME/CE Services Received Directly from a Commercial Supporter: Medical Contributor, Fox29 News
Accredited Provider Disclosure
The PIM planners and managers have nothing to disclose.
Planning Committee Disclosures
The peerXchange planners and managers have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and peerXchange. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee to participate in this activity. To obtain credit during the period July 31, 2018 through July 31, 2019, a score of 70% or better on the post-test is required. Participants must review all activity information, including the learning objectives, disclosure statements, and content. A statement of credit will be available to print from your CME History on myCME. Users must:
Read the learning objectives and faculty disclosures.
Participate in the activity.
Successfully complete the post-test, activity evaluation, and claim credit. A post-test score of 70% or higher is required, and you may retake the post-test up to 2 times to achieve a passing score.
Your certificate will be available to print from your CME History, located under My Account.